<i>EGFR</i> ex20ins+ NSCLC

CME

EGFR Exon 20–Altered NSCLC: A Personalized Approach to Improve Patient Outcomes

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: November 17, 2021

Expiration: November 16, 2022

Activity

Progress
1
Course Completed
Introduction

In this module, Nicolas Girard, MD, PhD, offers an overview of the role of EGFR exon 20 insertion mutations in non-small-cell lung cancer (NSCLC), including new data from studies presented at the 2021 International Association for the Study of Lung Cancer World Conference on Lung Cancer (WCLC) and the 2021 European Society for Medical Oncology (ESMO) Congress.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slidesets, which can be found here or downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. Several questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

If you are a practicing healthcare professional, how many patients with lung cancer do you provide care for in a typical month?

Which of the following assays is most appropriate to use for the detection of EGFR exon 20 insertion mutations based on sensitivity?

Which of the following most accurately describes the expected median progression-free survival (PFS) of patients with newly diagnosed advanced NSCLC with an EGFR exon 20 insertion mutation who receive the current standard of care platinum-based doublet chemotherapy?

A 66-year-old man with no history of smoking was diagnosed with metastatic nonsquamous NSCLC 1 year ago. Biomarker testing showed PD-L1 <1% by immunohistochemistry and an EGFR exon 20 insertion mutation by NGS. He received carboplatin/pemetrexed plus pembrolizumab. After 8 months of therapy, imaging showed progressive disease (PD).

In your current practice, which of the following therapies would you recommend for this patient with PD?